Fezakinumab
Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | IL-22 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6408H9873N1706O2016S44 |
| Molar mass | 144479.04 g·mol−1 |
  (what is this?) (verify) | |
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
- "Pfizer Pipeline" (PDF). 28 February 2011. Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.
- "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. Archived from the original on 24 January 2018. Retrieved 2017-06-07.
- Richardson B. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.